

#12741 Store at -20°C

LC3A/B (D3U4C) XP[®] Rabbit mAb



- Small 100 µl (10 western blots)
- Petite 40 µl (4 western blots)

Orders ■ 877-616-CELL (2355)
orders@cellsignaling.com

Support ■ 877-678-TECH (8324)
info@cellsignaling.com

Web ■ www.cellsignaling.com

rev. 07/22/14


For Research Use Only. Not For Use In Diagnostic Procedures.

Applications W, IHC-P, IF-IC, F Endogenous	Species Cross-Reactivity* H, M, R, (Mk, X, B, Dg, Pg)	Molecular Wt. 14, 16 kDa	Isotype Rabbit IgG**
--	--	-----------------------------	-------------------------


Background: Autophagy is a catabolic process for the autophagosomal-lysosomal degradation of bulk cytoplasmic contents (1,2). Autophagy is generally activated by conditions of nutrient deprivation, but it has also been associated with a number of physiological processes including development, differentiation, neurodegenerative diseases, infection, and cancer (3). Autophagy marker Light Chain 3 (LC3) was originally identified as a subunit of microtubule-associated proteins 1A and 1B (termed MAP1LC3) (4) and subsequently found to contain similarity to the yeast protein Apg8/Aut7/Cvt5 critical for autophagy (5). Three human LC3 isoforms (LC3A, LC3B, and LC3C) undergo post-translational modifications during autophagy (6-9). Cleavage of LC3 at the carboxy terminus immediately following synthesis yields the cytosolic LC3-I form. During autophagy, LC3-I is converted to LC3-II through lipidation by a ubiquitin-like system involving Atg7 and Atg3 that allows for LC3 to become associated with autophagic vesicles (6-10). The presence of LC3 in autophagosomes and the conversion of LC3 to the lower migrating form, LC3-II, have been used as indicators of autophagy (11).

Specificity/Sensitivity: LC3A/B (D3U4C) XP[®] Rabbit mAb recognizes endogenous levels of total LC3A and LC3B proteins.

Source/Purification: Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu44 of human LC3B protein (conserved in LC3A).



Western blot analysis of extracts from RD cells, untreated (-) or Torin 1-treated (250 nM, 4 hr); using LC3A/B (D3U4C) XP[®] Rabbit mAb.



Western blot analysis of extracts from HeLa, NIH/3T3, and KNRK cells, untreated (-) or chloroquine-treated (50 µM, overnight); using LC3A/B (D3U4C) XP[®] Rabbit mAb.

Entrez-Gene ID #84557, 81631
Swiss-Prot Acc. #Q9H492, Q9GZQ8

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.

***Species cross-reactivity is determined by western blot.**

****Anti-rabbit secondary antibodies must be used to detect this antibody.**

Recommended Antibody Dilutions:

Western blotting	1:1000
Immunohistochemistry (Paraffin)	1:1000†
Unmasking buffer:	Citrate
Antibody diluent:	SignalStain [®] Antibody Diluent #8112
Detection reagent:	SignalStain [®] Boost (HRP, Rabbit) #8114
†Optimal IHC dilutions determined using SignalStain [®] Boost IHC Detection Reagent.	
Immunofluorescence (IF-IC)	1:100
IF Protocol:	Methanol Fixation required
Flow Cytometry	1:100

For product specific protocols please see the web page for this product at www.cellsignaling.com.

Please visit www.cellsignaling.com for a complete listing of recommended complementary products.

Background References:


- (1) Reggiori, F. and Klionsky, D.J. (2002) *Eukaryot. Cell* 1, 11-21.
- (2) Codogno, P. and Meijer, A.J. (2005) *Cell Death Differ.* 12 Suppl 2, 1509-1518.
- (3) Levine, B. and Yuan, J. (2005) *J. Clin. Invest.* 115, 2679-2688.
- (4) Mann, S.S. and Hammarback, J.A. (1994) *J. Biol. Chem.* 269, 11492-11497.
- (5) Lang, T. et al. (1998) *EMBO J.* 17, 3597-3607.
- (6) Kabeya, Y. et al. (2000) *EMBO J.* 19, 5720-5728.
- (7) He, H. et al. (2003) *J. Biol. Chem.* 278, 29278-29287.
- (8) Tanida, I. et al. (2004) *J. Biol. Chem.* 279, 47704-47710.
- (9) Wu, J. et al. (2006) *Biochem. Biophys. Res. Commun.* 339, 437-442.
- (10) Ichimura, Y. et al. (2000) *Nature* 408, 488-492.
- (11) Kabeya, Y. et al. (2004) *J. Cell Sci.* 117, 2805-2812.

Alexa Fluor[®] is a registered trademark of Molecular Probes, Inc.
DRAQ5[®] is a registered trademark of Biostatus Limited.
Tween[®] is a registered trademark of ICI Americas, Inc.


IMPORTANT: For western blots, incubate membrane with diluted antibody in 5% w/v BSA, 1X TBS, 0.1% Tween[®] 20 at 4°C with gentle shaking, overnight.

© 2013 Cell Signaling Technology, Inc.
XP[®] and Cell Signaling Technology[®] are trademarks of Cell Signaling Technology, Inc.


Applications Key: W—Western IP—Immunoprecipitation IHC—Immunohistochemistry ChIP—Chromatin Immunoprecipitation IF—Immunofluorescence F—Flow cytometry E-P—ELISA-Peptide
Species Cross-Reactivity Key: H—human M—mouse R—rat Hm—hamster Mk—monkey Mi—mink C—chicken Dm—D. melanogaster X—Xenopus Z—zebrafish B—bovine
Dg—dog Pg—pig Sc—S. cerevisiae Ce—C. elegans Hr—horse All—all species expected Species enclosed in parentheses are predicted to react based on 100% homology.




Confocal immunofluorescent analysis of HeLa (upper) and C2C12 (lower) cells, chloroquine-treated (50 μ M, overnight; left), nutrient-starved with EBSS (3 hr, middle) or untreated (right) using LC3A/B (D3U4C) XP[®] Rabbit mAb (green) and β -Actin (13E5) Rabbit mAb (Alexa Fluor[®] 555 Conjugate) #8046 (red). Blue pseudocolor= DRAQ5[®] #4084 (fluorescent DNA dye).




Flow cytometric analysis of HeLa cells, untreated (blue) or treated with chloroquine (50 μ M, 16 hr) (green), using LC3A/B (D3U4C) Rabbit mAb. Anti-rabbit IgG (H+L), F(ab')₂ Fragment (Alexa Fluor[®] 647 Conjugate) #4414 was used as a secondary antibody.



Immunohistochemical analysis of paraffin-embedded NIH/3T3 cell pellets, control (left) or chloroquine-treated (right), using LC3A/B (D3U4C) XP[®] Rabbit mAb.



Immunohistochemical analysis of paraffin-embedded mouse prostate using LC3A/B (D3U4C) XP[®] Rabbit mAb.



Immunohistochemical analysis of paraffin-embedded human lung carcinoma using LC3A/B (D3U4C) XP[®] Rabbit mAb in the presence of control peptide (left) or antigen-specific peptide (right).